- Home
- AC vs DYN Comparison
AC vs DYN Comparison
Compare AC & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AC
- DYN
- Stock Information
- Founded
- AC 1976
- DYN 1984
- Country
- AC United States
- DYN United States
- Employees
- AC N/A
- DYN N/A
- Industry
- AC Investment Bankers/Brokers/Service
- DYN Medicinal Chemicals and Botanical Products
- Sector
- AC Finance
- DYN Health Care
- Exchange
- AC Nasdaq
- DYN Nasdaq
- Market Cap
- AC 809.6M
- DYN 848.8M
- IPO Year
- AC N/A
- DYN 2020
- Fundamental
- Price
- AC $35.80
- DYN $11.41
- Analyst Decision
- AC
- DYN Strong Buy
- Analyst Count
- AC 0
- DYN 12
- Target Price
- AC N/A
- DYN $47.00
- AVG Volume (30 Days)
- AC 4.8K
- DYN 2.9M
- Earning Date
- AC 05-08-2025
- DYN 05-08-2025
- Dividend Yield
- AC 6.06%
- DYN N/A
- EPS Growth
- AC 16.36
- DYN N/A
- EPS
- AC 1.80
- DYN N/A
- Revenue
- AC $12,293,000.00
- DYN N/A
- Revenue This Year
- AC N/A
- DYN N/A
- Revenue Next Year
- AC N/A
- DYN N/A
- P/E Ratio
- AC $19.82
- DYN N/A
- Revenue Growth
- AC N/A
- DYN N/A
- 52 Week Low
- AC $28.58
- DYN $6.36
- 52 Week High
- AC $43.85
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- AC 53.33
- DYN 55.69
- Support Level
- AC $34.30
- DYN $9.17
- Resistance Level
- AC $36.90
- DYN $12.47
- Average True Range (ATR)
- AC 1.02
- DYN 0.96
- MACD
- AC 0.13
- DYN 0.13
- Stochastic Oscillator
- AC 68.57
- DYN 67.88
About AC Associated Capital Group Inc.
Associated Capital Group Inc is a diversified global financial services company. It operates in the business of alternative investment management, institutional research services, and cash and other assets through subsidiaries. The activities of its subsidiaries comprise publishing daily research notes and full reports using private market value with a catalyst methodology and also products and customized solutions utilizing private market value with catalyst method of investing.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.